Translate the text from Welsh to English.



 
Mae'n bleser gennyf rannu'r newyddion bod Cylchlythyr Iechyd Cymru Cael gwared ar hepatitis (B a C) fel bygythiad i iechyd y cyhoedd yng Nghymru – Camau gweithredu ar gyfer 2022\-23 a 2023\-24 bellach wedi'i gyhoeddi. Bydd hyn yn helpu Cymru i gyflawni ein hymrwymiad i gyrraedd targedau Sefydliad Iechyd y Byd i gael gwared ar hepatitis B a C fel bygythiad i iechyd y cyhoedd erbyn 2030\.


Dros y blynyddoedd diwethaf, rydym wedi gwneud cynnydd sylweddol tuag at y nodau hyn. Mae tua 4,000 o bobl wedi cael eu trin yn llwyddiannus am hepatitis C, ond mae gwaith modelu diweddar yn amcangyfrif bod tua 8,000 o bobl yng Nghymru o hyd sy'n byw â hepatitis C.


Mae sgrinio am hepatitis B bellach yn rhan o'n rhaglen sgrinio cyn geni, ac mae'r rhaglen imiwneiddio rheolaidd i blant yn cynnwys brechiad hepatitis B, sy’n golygu bod achosion o haint hepatitis B acíwt ymhlith plant yn brin yng Nghymru erbyn hyn. Fodd bynnag, mae'n parhau'n broblem ymhlith oedolion heb eu brechu. 


Cafodd y pandemig effaith ddifrifol ar wasanaethau hepatitis B a C. Rwy'n falch bod y Cylchlythyr Iechyd Cymru hwn yn amlinellu sut y bydd y GIG yn mynd ati i adfer gwasanaethau i'w lefelau cyn y pandemig yn ogystal ag ailgydio yn yr ymdrechion i gael gwared ar hepatitis B a C fel bygythiad i iechyd y cyhoedd erbyn 2030\. Mae 13 o gamau allweddol i fyrddau iechyd, Byrddau Cynllunio Ardal ac Iechyd Cyhoeddus Cymru er mwyn sicrhau bod gwasanaethau rheng flaen yn cael y cymorth sydd ei angen er mwyn cyrraedd y targedau hyn i gael gwared ar y feirws.


Mae manteision cael gwared ar hepatitis B a C yn eang, i unigolion ac i'r gymdeithas ehangach. Drwy nodi a thrin pobl sydd â hepatitis B a C, gallwn sicrhau na fydd clefyd yr afu cysylltiedig â hepatitis yn datblygu, na'r cymhlethdodau sy'n deillio ohono, sy'n cael effaith sylweddol a niweidiol ar iechyd meddwl a chorfforol pobl. Yn ogystal, mae goblygiadau sylweddol o ran costau ac adnoddau i'r GIG o drin clefyd yr afu cysylltiedig â hepatitis.


Mae swyddogion wedi sefydlu Grŵp Trosolwg Rhaglen Dileu Hepatitis B a C sy'n cynnwys amrywiaeth eang o randdeiliaid er mwyn rhoi pwyslais strategol unwaith yn rhagor ar gael gwared ar y feirws. Bydd y grŵp hwn yn adrodd i'r Prif Swyddog Meddygol a Gweinidogion yn rheolaidd.


Mae’r camau wedi cael eu datblygu gan y grŵp hwn, gan ganolbwyntio ar nodi’r bobl hynny y mae angen iddynt gael eu profi a'u trin, symleiddio prosesau darparu gwasanaethau fel bod modd i bobl gael eu profi a'u trin yn hawdd er mwyn diwallu anghenion unigolion, a chefnogi pobl drwy gydol y broses profi a thrin.


Rwy'n ddiolchgar am y gwaith caled a wnaed yn y maes hwn hyd yma, ac yn edrych ymlaen at gefnogaeth barhaus wrth inni fynd ati i gael gwared ar hepatitis B a C fel bygythiad i iechyd y cyhoedd.







Translation:


 
I am pleased to announce the publication of the *Eliminating hepatitis (B and C) as a public health threat in Wales – Actions for 2022\-23 and 2023\-24* Welsh Health Circular. This will help Wales to deliver our commitment to achieve the World Health Organisation’s targets to eliminate hepatitis B and C as a public health threat by 2030\.


In recent years, we have made some real progress towards these goals. Some 4,000 people have successfully been treated for hepatitis C but recent modelling estimates there are still around 8,000 people in Wales living with hepatitis C.


Hepatitis B screening is now included in our antenatal screening programme and hepatitis B vaccination is part of the routine childhood immunisation programme, which means that acute hepatitis B infection in Wales is now rare in children. However, it remains a problem among unvaccinated adults.


Hepatitis B and C services were severely impacted by the pandemic. I am pleased this Welsh Health Circular sets out how the NHS will not only recover services to pre\-pandemic levels but reinvigorate the drive to eliminate hepatitis B and C as a public health threat by 2030\. There are 13 key actions for health boards, Area Planning Boards and Public Health Wales to ensure frontline services are provided with the support needed to achieve these elimination targets.


The benefits of eliminating hepatitis B and C are wide ranging, both to individuals and to wider society.  By identifying and treating people with hepatitis B and C, we can prevent the development of hepatitis\-related liver disease and its complications, which have a significant and detrimental impact on people’s mental and physical health. Additionally, there are significant cost and resource implications to the NHS in treating hepatitis\-related liver disease.


Officials have established a Hepatitis B and C Elimination Programme Oversight Group, which includes a wide range of stakeholders to provide a renewed strategic focus on elimination and will report to the Chief Medical Officer and Ministers on a regular basis.


The actions have been developed by this group with a focus on identifying those who need testing and treatment; simplifying service delivery so testing and treatment is accessible to meet the needs of individuals, and supporting people through the testing and treatment process.


I am grateful for all the hard work that has gone into this area to date, and look forward to continued support in our drive to eliminate hepatitis B and C as a public health threat.